Cardioxyl Pharmaceuticals.

PositionTRIANGLE REGION

CHAPEL HILL -- Bristol-Myers Squibb will acquire Cardioxyl Pharmaceuticals for $300 million. The New York-based drugmaker could pay an additional $1.8 billion if certain development, regulatory and sales milestones are met. Started in Maryland in 2005, Cardioxyl moved...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT